AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Edcross 1.5mg Injection

Prescription Icon
Prescription Required

Marketer

Biophar Lifesciences Pvt Ltd

Salt Composition

Edaravone (1.5mg)

Overview Edcross 1.5mg Injection

Neuro-Guard 1.5mg Injection treats amyotrophic lateral sclerosis (ALS), a debilitating neurological disorder causing muscle weakness and functional impairment. This antioxidant medication mitigates nerve cell damage, thereby slowing disease advancement. Administered intravenously by a medical professional only—never self-inject—it's indicated when oral intake is infeasible. Follow your physician's prescribed dosage and regimen. If a dose is missed, take it immediately upon recollection. Commonly reported adverse effects include cephalalgia, ecchymosis, and gait abnormalities. Localized injection-site reactions (pain, erythema, edema) may occur, typically resolving spontaneously. Persistent or bothersome symptoms warrant medical consultation. Report any allergic responses, such as pruritus or orofacial swelling, immediately, as these necessitate prompt medical intervention.

Uses of Edcross 1.5mg Injection

Lou Gehrig's disease

Major Benefits of Edcross 1.5mg Injection:

This medication will be administered by your physician or their qualified staff. Self-medication is strongly discouraged.

Common Side effects of Edcross 1.5mg Injection:

  • Bruise
  • Walking difficulties
  • Headache
  • Injection site reactions (pain, swelling, redness)

How to use Edcross 1.5mg Injection:

This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.

How Edcross 1.5mg Injection works:

Neuro-protective Edcross 1.5mg Injection functions as an antioxidant, bolstering nerve health and mitigating the damage inflicted by free radicals. Its mechanism involves slowing neurological deterioration, thereby delaying the onset of amyotrophic lateral sclerosis (ALS) symptoms through the reduction of oxidative stress within the brain.

SAFETY ADVICE

AlcoholAlcoholCONSULT YOUR DOCTOR

Alcohol consumption with Edcross 1.5mg Injection may be unsafe; seek medical advice before combining them.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Edcross 1.5mg Injection during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to the fetus. A physician will assess the potential advantages against any possible dangers prior to prescription. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Data on the compatibility of Edcross 1.5mg Injection with breastfeeding are unavailable. Seek medical advice from your physician.

DrivingDrivingCONSULT YOUR DOCTOR

The impact of Edcross 1.5mg Injection on driving ability is undetermined. Refrain from operating a vehicle if you experience symptoms impairing concentration or reaction time.

KidneyKidneyCONSULT YOUR DOCTOR

Insufficient data exists regarding the administration of Edcross 1.5mg Injection to individuals with renal impairment. Seek medical advice from your physician.

LiverLiverCAUTION

Administering Edcross 1.5mg Injection to patients with severe hepatic impairment requires careful consideration and potential dose modification. Data regarding Edcross 1.5mg Injection use in such patients is limited. Physician consultation is advised. Dosage changes are not typically necessary for individuals with mild or moderate liver dysfunction.

What if you forget to take Edcross 1.5mg Injection :

NA

Facts to Know About Edcross 1.5mg Injection

LabelValue
Type of Compound Pyrazolone-based compounds
Potential for Dependence None.
Type of Medication Nervous system medication
Mechanism of Action Cognitive enhancer

FAQs on Edcross 1.5mg Injection

Edcross 1.5mg Injection may cause side effects such as disorientation, headache, and gait disturbances. Less frequently reported adverse reactions include skin reactions (rash and pruritus), respiratory distress (dyspnea, chest constriction, wheezing, cough), particularly in asthmatic individuals, and mycoses.
The injectable formulation of Edcross, 1.5mg, is a solution administered intravenously over one hour by a qualified medical professional within a clinical setting. Initially, it's typically administered daily for the first two weeks of a four-week treatment cycle. Subsequent cycles usually involve daily injections for the first ten days of a four-week cycle. Dosage frequency is determined by the physician based on individual patient response.
The injectable medication Edcross, at a dosage of 1.5mg, is indicated for the management of amyotrophic lateral sclerosis (ALS). ALS is a progressive neurodegenerative disease characterized by the gradual deterioration of motor neurons, leading to muscle atrophy and weakness. Edcross 1.5mg Injection functions by mitigating the neuronal damage linked to ALS symptom progression.
Tell your physician or pharmacist about any allergies you have, including allergies to edaravone, other drugs, sodium bisulfite, or any Edcross 1.5mg Injection component. Before starting edaravone, disclose all current medications, vitamins, and supplements – both prescription and over-the-counter – to your doctor. Dose adjustments or close monitoring for side effects may be necessary. Inform your doctor of any history of asthma, or if you are pregnant, planning pregnancy, or breastfeeding. Contact your doctor immediately if you become pregnant during edaravone treatment.
Research has yet to determine whether ALS is preventable. Nevertheless, understanding associated risk factors may lessen the likelihood of developing the condition. These factors include tobacco use and contact with pesticides and insecticides. Furthermore, evidence indicates a heightened ALS risk among military veterans.
Individuals of Caucasian and non-Hispanic descent exhibit the highest incidence of this disease. A familial component is present in approximately 5–10% of all cases, indicating a hereditary transmission from parents. Onset can occur at any age, though symptoms typically manifest between 55 and 75 years of age. A slightly elevated risk is observed in men compared to women; this disparity diminishes with increasing age. Research indicates a potential 1.5–2 fold increased risk among military veterans, possibly attributed to exposure to toxins during service.
Studies propose a link between exposure to toxins in combat or intense physical exertion and a heightened ALS risk among veterans and athletes.
Initial ALS manifestations can involve muscle fasciculations in the limbs or tongue, muscle spasms, muscular rigidity (spasticity), and weakness affecting an arm, leg, neck, or diaphragm. Speech may become slurred or nasal, and chewing or swallowing can become difficult. The onset frequently presents as hand or arm weakness, hindering simple actions like buttoning clothing, writing, or manipulating a key. Alternatively, leg weakness may be the primary symptom, causing gait difficulties, increased tripping, or stumbling.
Edcross 1.5mg Injection
406
MRP 495
17% off